Every November #movember turns the spotlight on men’s health and prostate cancer with the hope of provoking men to pay attention to early signs of cancer, and encouraging them to get screened early.
Prostate cancer is the most common cancer among men in many parts of the world. In 2018, it is estimated there were around 1,271,000 new cases of prostate cancer worldwide. In Finland, around 5000 men are diagnosed with prostate cancer every year, and 850 men die of the disease.
Detecting potentially lethal prostate cancer variants at an early stage is the most important objective for prostate cancer screening. The lethal variations also generate the biggest costs for healthcare. Currently, population-level screenings are not conducted because of the deficiencies of current screening methods. To make large-scale screenings a concrete possibility, the current testing methods need a new complementary addition.
The current screening methods need complementary tests
The PSA-test is a blood test that measures the level of prostate-specific antigen in the blood. Currently, it is the most widely used screening test for prostate cancer, but its suitability for large-scale screenings remains controversial. The PSA-test has a low specificity in detecting the most dangerous types of prostate cancer, which leads to the unnecessary treatment of tens of thousands of men every year, which in turn creates a significant financial burden.
The limitations of the PSA screening test do not mean that all large-scale screenings are ineffective. Research has shown that when it comes to prostate cancer, even the less-than-accurate PSA-test has had a positive effect on the mortality rate. To achieve even better results with large-scale screening, the PSA test needs to be complemented with another test that does not focus only on the presence of the prostate-specific antigen in a sample, but also on other disease indicators.
Aqsens Health’s method provides enhanced specificity for the detection of lethal and metastatic cancers
Rather than measuring only the PSA-levels in a blood sample, Aqsens Health’s s E-TRF -based test combines different measurements from urine to detect the cancer. Using biological samples like urine makes sample collection a quick, easy, and an affordable process.
Aqsens Health’s preliminary research results suggest that its test has the capability to classify the different types of prostate cancer, which would bring great improvements to the detection of lethal and metastatic variants of prostate cancer. The high specificity and sensitivity of the E-TRF method and its immunity to sample variations make it a reliable tool for detecting prostate cancer, and when used in addition to the current screening methods it can bring a significant improvement to preventive prostate cancer screening.